Removal of basiliximab by plasmapheresis.

C. N. Okechukwu, H. U. Meier-Kriesche, D. Armstrong, D. Campbell, C. Gerbeau, B. Kaplan

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Basiliximab is a chimeric monoclonal antibody directed against the alpha chain of interleukin-2 (IL-2) receptors. Given its expected volume of distribution (plasma volume), therapeutic plasmapheresis may be expected to lower serum Basiliximab levels. A 20-mg dose of Basiliximab was given before plasmapheresis. Blood and pheresis fluid samples were obtained to monitor Basiliximab levels. A total of three blood samples were drawn: the first was obtained 4 hours before, the second sample immediately before commencement, and the third 2 hours after cessation of plasmapheresis. A fourth sample was obtained from the removed plasma. There was an appreciable reduction in Basiliximab concentration levels after plasmapheresis. From the change in serum concentration after plasmapheresis, approximately 64.6% of circulating Basiliximab was removed. Plasmapheresis removes substantial amounts of Basiliximab. Therefore, supplemental Basiliximab should be given after plasmapheresis to maintain the desired duration of IL-2R saturation.

Original languageEnglish (US)
JournalAmerican Journal of Kidney Diseases
Volume37
Issue number1
StatePublished - 2001
Externally publishedYes

Fingerprint

Plasmapheresis
Interleukin-2 Receptor alpha Subunit
Blood Component Removal
basiliximab
Plasma Volume
Serum
Monoclonal Antibodies

Cite this

Okechukwu, C. N., Meier-Kriesche, H. U., Armstrong, D., Campbell, D., Gerbeau, C., & Kaplan, B. (2001). Removal of basiliximab by plasmapheresis. American Journal of Kidney Diseases, 37(1).

Removal of basiliximab by plasmapheresis. / Okechukwu, C. N.; Meier-Kriesche, H. U.; Armstrong, D.; Campbell, D.; Gerbeau, C.; Kaplan, B.

In: American Journal of Kidney Diseases, Vol. 37, No. 1, 2001.

Research output: Contribution to journalArticle

Okechukwu, CN, Meier-Kriesche, HU, Armstrong, D, Campbell, D, Gerbeau, C & Kaplan, B 2001, 'Removal of basiliximab by plasmapheresis.', American Journal of Kidney Diseases, vol. 37, no. 1.
Okechukwu CN, Meier-Kriesche HU, Armstrong D, Campbell D, Gerbeau C, Kaplan B. Removal of basiliximab by plasmapheresis. American Journal of Kidney Diseases. 2001;37(1).
Okechukwu, C. N. ; Meier-Kriesche, H. U. ; Armstrong, D. ; Campbell, D. ; Gerbeau, C. ; Kaplan, B. / Removal of basiliximab by plasmapheresis. In: American Journal of Kidney Diseases. 2001 ; Vol. 37, No. 1.
@article{93c46318c15746968b7fbee7d86fbce4,
title = "Removal of basiliximab by plasmapheresis.",
abstract = "Basiliximab is a chimeric monoclonal antibody directed against the alpha chain of interleukin-2 (IL-2) receptors. Given its expected volume of distribution (plasma volume), therapeutic plasmapheresis may be expected to lower serum Basiliximab levels. A 20-mg dose of Basiliximab was given before plasmapheresis. Blood and pheresis fluid samples were obtained to monitor Basiliximab levels. A total of three blood samples were drawn: the first was obtained 4 hours before, the second sample immediately before commencement, and the third 2 hours after cessation of plasmapheresis. A fourth sample was obtained from the removed plasma. There was an appreciable reduction in Basiliximab concentration levels after plasmapheresis. From the change in serum concentration after plasmapheresis, approximately 64.6{\%} of circulating Basiliximab was removed. Plasmapheresis removes substantial amounts of Basiliximab. Therefore, supplemental Basiliximab should be given after plasmapheresis to maintain the desired duration of IL-2R saturation.",
author = "Okechukwu, {C. N.} and Meier-Kriesche, {H. U.} and D. Armstrong and D. Campbell and C. Gerbeau and B. Kaplan",
year = "2001",
language = "English (US)",
volume = "37",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Removal of basiliximab by plasmapheresis.

AU - Okechukwu, C. N.

AU - Meier-Kriesche, H. U.

AU - Armstrong, D.

AU - Campbell, D.

AU - Gerbeau, C.

AU - Kaplan, B.

PY - 2001

Y1 - 2001

N2 - Basiliximab is a chimeric monoclonal antibody directed against the alpha chain of interleukin-2 (IL-2) receptors. Given its expected volume of distribution (plasma volume), therapeutic plasmapheresis may be expected to lower serum Basiliximab levels. A 20-mg dose of Basiliximab was given before plasmapheresis. Blood and pheresis fluid samples were obtained to monitor Basiliximab levels. A total of three blood samples were drawn: the first was obtained 4 hours before, the second sample immediately before commencement, and the third 2 hours after cessation of plasmapheresis. A fourth sample was obtained from the removed plasma. There was an appreciable reduction in Basiliximab concentration levels after plasmapheresis. From the change in serum concentration after plasmapheresis, approximately 64.6% of circulating Basiliximab was removed. Plasmapheresis removes substantial amounts of Basiliximab. Therefore, supplemental Basiliximab should be given after plasmapheresis to maintain the desired duration of IL-2R saturation.

AB - Basiliximab is a chimeric monoclonal antibody directed against the alpha chain of interleukin-2 (IL-2) receptors. Given its expected volume of distribution (plasma volume), therapeutic plasmapheresis may be expected to lower serum Basiliximab levels. A 20-mg dose of Basiliximab was given before plasmapheresis. Blood and pheresis fluid samples were obtained to monitor Basiliximab levels. A total of three blood samples were drawn: the first was obtained 4 hours before, the second sample immediately before commencement, and the third 2 hours after cessation of plasmapheresis. A fourth sample was obtained from the removed plasma. There was an appreciable reduction in Basiliximab concentration levels after plasmapheresis. From the change in serum concentration after plasmapheresis, approximately 64.6% of circulating Basiliximab was removed. Plasmapheresis removes substantial amounts of Basiliximab. Therefore, supplemental Basiliximab should be given after plasmapheresis to maintain the desired duration of IL-2R saturation.

UR - http://www.scopus.com/inward/record.url?scp=0035220454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035220454&partnerID=8YFLogxK

M3 - Article

C2 - 11136200

AN - SCOPUS:0035220454

VL - 37

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 1

ER -